Prevalence of chronic kidney diseases and determinants among TDF users of pregnant and lactating women based on eGFR-cg, and MDRD-4 in hospital setting of north east Amhara, Ethiopia

 
 
 
  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract


    In recent days, it is common to see increasing incidence of Fanconi, proximal kidney tubular damage and chronic kidney diseases-CKD among high risk populations that drew the clinicians’ attention to monitor closely. Among these risk populations with potential CKD incidence; HIV positive patients who uses TDF as a component of HAART need to be monitored for the incidence of CKD as a toxicity of TDF before initiation and during treatment despite the fact that the current monitoring practice in Ethiopia in most hospitals remain to be poor. Hence this study aimed at measuring the incidence of CKD among high risk segment of HIV positive pregnant and lactating women who uses TDF as part of their HAART treatment. Using a non-proportionate stratified sampling, a total of 111 HIV+ pregnant and lactating women who are on TDF based HAART treatment were enrolled to measure the incidence of CKD based on NKF K/DOQI Classification. Using the Android application of Medicalc GFR-cg, and MDRD-4; the prevalence of stage-2 CKD was 16.2 % (60-89 ml/min) and Stage 5-CKD/Renal Failure who require dialysis were 3.6% (CrCl < 15ml/min/1.72m2) by both method of calculation CrCl (GFR-cg and MDRD-4). Women who were lactating had a relative risk of 0.918 (95% CI lies within 0.845-0.998) of acquiring CKD (P= 0.045). The other associated factors were BMI less than 18.5 (P= 0.004 and adjusted OR of 7.82), WHO clinical stage-1 (P=0.014, odds ratio of 5.4 and 95% CI of 1.24-24.42), baseline CD4 count > 500 (P=0.02), and duration on TDF (> 12 months on treatment) and low haematocrit of 30 had a higher risk of falling into Stage 2 CKD with cohort risk estimate of 4.103 (95 % CI of 1.02, 16.54). The risk estimate of WHO stage 2 to acquire stage-4 CKD was 1.087 (95% CI of 1.002, 1.180) statistically significant (P=0.05.). The prevalence of stage 2 CKD among pregnant and lactating women by GFR-cg method of calculation was higher than MDRD-4 calculation. In this study, MDRD-4 method underestimated stage 2 CKD. Hence it is worth and highly recommended to use GFR-cg method in the baseline and during treatment monitoring of TDF toxicity to the kidney particularly for diagnosing the early stage of CKD.


  • Keywords


    Acute Kidney Injury; Chronic Kidney Disease; Creatinine Clearance; Glomerular Filtration Rate; Modified Renal Diet Diseases; Renal Fail-ure; TDF.

  • References


      [1] WHO. (2014), HIV/AIDS. Mother-to-child transmission of HIV.

      [2] Gobalappa C, Stover J. (2014). The cost benefit of B+ option for the prevention of mother-to- child transmission of HIV/AIDS. Jan; 28.

      [3] Ethiopian FMOH. (2013), National B+ Option PMTCT guideline.

      [4] Christopher A Fux, Mathew Simcock. (2014), TDF use is associated with reduction in calculated GFR in Swiss HIV cohort. Antiretroviral therapy.

      [5] Joel G, Schlomo S. (2004), Efficacy and safety of TDF versus Stavudine combination HAART in treatment naive patients, a 3 year randomized trial. JAMA. 292(2):191-201. https://doi.org/10.1001/jama.292.2.191.

      [6] Mohammed I. Danjuma, Nurul H. Mohammed. (2014), an investigation of the pattern of kidney injury in HIV positive person exposed to Tenofovir Disoproxil fumarate: an examination of large population data base (MHRA database). Int. Journal STD AIDS. 24(4):273-279. https://doi.org/10.1177/0956462413504747.

      [7] Andreia M, Jorge T Jr. (2012), Prevalence and risk factor associated with to Chronic Kidney disease in HIV infected patients on HAART and undetectable viral load in Brazil... PLoS One.

      [8] Derek C. (2012), Tenofovir Use and Renal Insufficiency among Pregnant and General Adult Population of HIV infected, ART-Naive Individuals in Lilongwe. PLoS One -7.

      [9] Ethiopian Demographic and Health Survey.2011.

      [10] Stefan M, Florian B. (2005), antiretroviral therapy with Tenofovir is associated with mild renal dysfunction. AIDS, 19:93-99. https://doi.org/10.1097/00002030-200501030-00012.

      [11] Patricia M. Flynn, Mark M. (2011), Pharmacokinetics and safety of single dose TDF and Emtricitabine in HIV infected pregnant women and their infants. American society for microbiology.

      [12] Sergio P, Felix G. (2005), Low frequency renal function impairment during one-year of therapy with TDF containing regimen in real world. AIDS patients care and STDs. July 19(7):421-424.

      [13] Benjamin Y, Kate B. (2009) Renal function in patients with pre-existing renal disease receiving TDF containing HAART. AIDS patient care and STDs. August; 23(8).

      [14] Steven V, Katarina K. (2011), Prevalence of renal impairment among HIV-infected antiretroviral person eligible for HAART in rural Zimbabwe. Medicine sans Frontier.

      [15] Pablo L, Pablo B. (2009), Kidney tubular dysfunction in the absence of impaired Glomerular filtration dysfunction. AIDS. 23:689–696. https://doi.org/10.1097/QAD.0b013e3283262a64.

      [16] Primary care of Veterans with HIV. (2009). Renal disease: Organ system and metabolic. April 2009, latest updated October 2011.

      [17] Gallant, E. (2008), A 3-year renal safety of TDF versus thymidine analogue containing regimen HAART in treatment naive patients. AIDS. October :22(16)

      [18] Leigh P, Doug T. (2007), TDF for prevention of HIV infection in Women: A phase 2 double blind randomized placebo control, trial.

      [19] Poizot M, Solas C. (2013), renal impairment in patients receiving TDB based combined ART: Impact of TDF trough concentration. J Acquired Immune Deficiency Syndrome.

      [20] Santiago M, Pere D, et al. (2006), Renal safety of TDF in HIV-1 treatment experience patients’ adverse event related to prior NRTI use: Data from a prospective, observational and multicenter study. J Acquired Immune Deficiency Syndrome. July; 42 (3).

      [21] Hana M, Larry T, et al. (2006), Serum creatinine changes in HIV sero-positive patients receiving TDF. AIDS. 20 (5)

      [22] K/DOQI Guideline for CKD.

      [23] Mark D, Abby G, et al, (2013), Tenofovir associated proteinuria. AIDS.2013; 27:479–485. https://doi.org/10.1097/QAD.0b013e32835883bf.


 

View

Download

Article ID: 8231
 
DOI: 10.14419/ijh.v6i1.8231




Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.